Immunotherapy is a promising treatment modality that acts by selectively harnessing the host immune defenses against cancer. An effective immune response is often needed to eliminate tumors following treatment which can trigger the immunogenicity of dying tumor cells. Some treatment modalities (such as photodynamic therapy, high hydrostatic pressure or radiotherapy) and agents (some chemotherapeutic agents, oncolytic viruses) have been used to endow tumor cells with immunogenicity and/or increase their immunogenicity. These treatments and agents can boost the antitumor capacity by inducing immune responses against tumor neoantigens. Immunogenic cell death is a manner of cell death that can induce the emission of immunogenic damage-associated molecular patterns (DAMPs). DAMPs are sufficient for immunocompetent hosts to trigger the immune system. This review focuses on the latest developments in the treatment modalities and agents that can induce and/or enhance the immunogenicity of cancer cells.
REVIEW
of DAMPs. The crucial DAMPs, which can induce ICD, include calreticulin (CRT), high mobility group box 1 (HMGB1), adenosine-5'-triphosphate (ATP) and heat shock protein (HSP) 70 and 90 (5) . These DAMPs bind to their own receptors, and recruit and activate immune cells. Finally, they lead to ingestion by professional phagocytes and present neoantigens to T lymphocytes to eliminate tumor cells (2) . The ability of DAMPs elicited during ICD is endoplasmic reticulum (ER) stress dependent, either accompanied or triggered by reactive oxygen species (ROS) (3, 6) .
CRT is the largest fraction; it is normally secluded in the ER lumen and relocates to the cell surface in the early course of ICD. The exposure of CRT may be linked to ER stress. CRT acts not only as an important "eat-me" signal for professional phagocytes but also as a central anticancer immunity mediator, thus playing a key role in inducing an antitumor immune response (7) . The underlying mechanisms have not been fully elucidated. The existing evidence indicates that CRT exposure is one of the important checkpoints determining the immunogenicity of dead cells. CRT-exposing cells are recognized and phagocytosed mostly by macrophages and dendritic cells (DCs) (8) . DCs are professional antigen-presenting cells. They play a vital role in triggering the immune response against tumor neoantigens and their activation is necessary for cancer elimination (2, 9) .
It is widely believed that ATP released from dying cancer cells is required for inducing the immune response (10) . Extracellular ATP not only acts as a "find-me" signal that promotes the rapid attraction of antigen-presenting cells to the location of the dying cancer cells (11) , but also binds to P2RX7 receptors on the surface of these cells. Therefore the NLRP3 inflammasome is activated (10) . During the intracellular ATP
Introduction
It is generally accepted that cancer derives from the interaction of genetic and epigenetic alterations that bring about cell immortality but simultaneously create neoantigens. Neoantigens are encoded by tumor-specific mutated genes and can be detected by the host immune system. Immunotherapy exploits the host immune system to recognize, target and destroy cancer, and offers a promising modality for the treatment of cancer (1) . There is increasing evidence that triggering antitumor immune responses accompanied by the death of tumor cells can provide long-term therapeutic effects (2) . This may be realized by stressing or damaging tumor cells, along with the release or emission of signals called damage-associated molecular patterns (DAMPs). DAMPs serve as danger signals and enhance the dying cells' immunogenicity (2, 3) . This cell death routine is referred to as immunogenic cell death (ICD).
ICD is defined as a cell death modality that effectively stimulates the immune response against neoantigens produced by dying or dead cells, in particular when they are derived from cancer cells (4) . ICD is characterized by exposure of "eat-me" signals on the cell surface through the release relocates from lysosomes to autolysosomes in response to ICD inducers, the lysosomal protein LAMP1 takes part in this process (12) . Studies indicated that extracellular ATP could increase the motility of both DCs (13) and tumor cells (14) . In addition, ATP can stimulate the maturation of DCs and increase the expression of the costimulatory molecules CD40, CD80 and CD86 (15) . The secretion of ATP mostly relies on the apoptotic stage and the type of stress or stimulus of cell death that induces ICD (3).
HSP70 and HSP90 are 2 chaperone proteins. They are normally located in the intracellular compartment and have cytoprotective functions. The release or surface expression of HSP70 and HSP90 either offers the direct immunogenic signal for immune system activation (especial DC activation) or acts as a vehicle for peptide antigen exposure (16) . A study indicated that the exposure of HSP90/HSP70 facilitated DC maturation (17) .
HMGB1, another important immunogenic molecule, is elicited when the plasma membrane is severely damaged. It acts as a proinflammatory signal and is able to trigger a potent immune response (18) . HMGB1 can bind to the tolllike receptor 4 (TLR4) on the surface of DCs (19) . The binding accelerates antigens to be uptaken, transported and processed in the DCs. It facilitates the presentation of antigens to T cells.
Recent studies indicated that some therapeutic modalities or agents could induce ICD, such as chemotherapeutic agents, photodynamic therapy, radiotherapy (6), multiple oncolytic viruses (20) , high hydrostatic pressure (21), shikonin (22) and capsaicin (23) . The gold standard to identify bona fide ICD inducers are vaccination experiments in vivo. The tumor cells are pretreated with ICD inducers and inoculated into immunocompetent mice. The mice are able to protect themselves from the subsequent challenge with the same syngeneic cancer cells (24) .
Cancer treatment modalities and antitumor agents as inducers of ICD

Chemotherapeutic agents
The conventional chemotherapeutic agents have been the main agents to treat cancer for a long time, and have been conventionally believed to directly kill tumor cells through their cytostatic/cytotoxic effects and trigger tumor cell death in an immunologically silent manner. However, accumulating evidence demonstrates that a decisive contribution to the long-term successful elimination of cancer by some traditional chemotherapeutic agents is made by triggering anticancer immune responses (25, 26) . The possible mechanism by which dying or dead tumor cells can induce an anticancer immune response is their immunogenic properties (5, 7), which trigger the specific signaling pathways that prompt DCs to phagocytose the tumor cell debris and facilitate the maturation of DCs.
Recent evidence suggested that some chemotherapeutic drugs, such as anthracyclines (doxorubicin, idarubicin, epirubicin, mitoxantrone), platinum derivatives (oxaliplatin), alkylating agents (cyclophosphamide) and proteasome inhibitors (bortezomib) were able to trigger ICD (26) . This ability to induce ICD relies on the generation of ROS and ER stress (6) .
Oxaliplatin is a third-generation platinum compound that was initially developed to avoid the resistance of tumor cells to first-and second-generation platinum compounds (27) . Besides its direct cytotoxic effects, oxaliplatin may also exert clinical effects via indirect activation of the immune system through inducing ICD (19) . Oxaliplatin induces immune responses against both transplantable and transgene-driven cancers in mice (28) . Exposure of tumor cells to oxaliplatin leads to release of HMGB1, which activates DCs in a TLR4-dependent manner (19) . Oxaliplatin also induces an ER stress response that triggers the translocation of CRT to the plasma membrane (28) . A study indicated that amphiphilic diblock copolymer nanoparticles (NPs) can enhance the ability of oxaliplatin to induce ICD. The cancer cells, when treated with NP-encapsulated oxaliplatin (NP-OXA), elicited more DAMPs and triggered more effective immune responses than oxaliplatin alone. In addition, the therapeutic effect was significantly higher in the NP-OXA group than in the oxaliplatin group. Furthermore, NP-OXA treatment facilitated a higher proportion of cytotoxic T lymphocytes (CTLs) to infiltrate into tumor tissue (29) .
Cyclophosphamide is a DNA alkylating agent in the family of nitrogen mustards (30) . It induces tumor cell death with clearcut immunogenic features. The antitumor effects of cyclophosphamide were effectively enhanced by type I interferons (IFN-I). The synergism of cyclophosphamide and endogenous IFN-I preferentially expanded CD8α+ DCs and led to a stronger antitumor response (31) . DCs play a vital role in the course of chemotherapy (2, 9) . Doxorubicin, a natural compound, is an anthracycline antibiotic (32) . A study indicated that subcutaneous inoculation of cancer cells that had been pretreated with doxorubicin in vitro was able to protect syngeneic mice against rechallenge with the same type of tumor cells but not with tumor cells of distinct origin (33) . This indicated that doxorubicin is an ICD inducer.
Mice vaccinated with DCs loaded with bortezomibpretreated breast cancer cells did not form transplantable tumors (34) . This indicated that the dying cancer cells had immunogenic features and that bortezomib is an ICD inducer. It was hypothesized that natural killer cells and CD8+ T cells, but not CD4+ T cells, were responsible for inhibiting tumor growth following bortezomib treatment (35) . Bortezomib also induces primary effusion lymphoma (PEL) cell apoptosis and promotes DC maturation. Bortezomib treatment triggers the relocation of CRT, HSP90 and HSP70 to the surface of dying PEL cells. Expression of these molecules leads to immune activation (36) .
Distinct chemotherapeutic agents, such as docetaxel, cisplatin and 5-fluorouracil, are not equivalent in their ability to trigger ICD. Cancer cells treated with docetaxel did not trigger classic ICD; however, CRT membrane translocation was observed after docetaxel treatment. When treated with docetaxel, tumor cells went through immunogenic modulation and obviously enhanced the ability of antigen-specific CTLs to kill tumor cells. This also indicated that docetaxel may enhance the immunogenicity of cancer cells, although it could not to induce ICD (25, 37) .
Oncolytic viruses
Immune responses against tumors share many features with those against viruses. Mimicking a viral infection is also a possible strategy for tumor immunotherapy. The attraction of oncolytic virus (OV) therapy is the very high therapeutic index. Some selective virus strains induced oncolysis to eliminate massive tumor in multiple cell death manners (38) . The lytic potential of OVs relies on the species of virus, the dose, and the natural and viral tropism. Recent preclinical studies showed that the major therapeutic effect of OVs is immune mediated rather than by direct oncolysis (39, 40) . The main mechanism consists of the induction of ICD of tumor cells through ER stress and the subsequent elicitation of a cascade of downstream comprehensive and complicated immune responses (41) . This involves the release of DAMPs and neoantigens from the dying cancer cells and their presentation to the immune system, leading to the activation of antitumor immune responses. The DAMPs include CRT, HSPs, HMGB1 and ATP (39, 42) . Antigen-presenting cells phagocytose tumor-associated antigens, migrate to the lymph nodes, and present antigens to T cells to establish the antitumor immune response. DAMPs also are potent inducers of innate immune cells. Therefore, the activation of both innate and adaptive immune responses is owed to the total effect of OV therapy (40) .
OVs are a potential treatment modality for cancer. A few OVs have been tested in randomized clinical trials. Among the group of OVs, adenoviruses, coxsackieviruses, reoviruses, vaccinia virus, Newcastle disease virus (NDV), measles virus (MV) and herpes simplex virus (HSV) are able to induce ICD (43) (44) (45) (46) (47) .
MV has been recognized to induce spontaneous cancer remission, and has been studied at the preclinical and clinical stages for its potential as a therapeutic OV (48, 49) . The death of melanoma cells, when mediated by MV infection, is an inflammatory reaction. MV-infected melanoma cells generate multiple inflammatory cytokines. MV boosts the innate antitumor response and MV-mediated melanoma cell death is able to trigger the specific adaptive immune response against melanoma. This suggests that MV is a potential OV for the treatment of melanoma. The suitable inflammatory environment may facilitate DC activation (44) .
The viruses applicable in oncolytic virotherapy (OVT) have the ability to infect and lyse cancer cells. NDV infected GL261 glioma cells and led to ICD including CRT surface translocation, release of HMGB1, and increase in antigen expression (45) . In vivo, the percentage of IFN-r+ cells within the CD8+ and CD4+ T cell fractions was significantly increased in the NDV-treated tumor microenvironment in contrast to the placebo-treated controls, along with decreased accumulation of myeloid-derived suppressor cells (45) . HSV-2 generated DAMPs in murine mammary gland cancer cells. However, HSV-1 was found to have less ability to induce DAMPs (50). RH2 is an oncolytic HSV-1 mutant that has the deficient neurovirulent γ134.5 gene and mutated gB gene. A study indicated that HSV-1 RH2 can lead squamous cell carcinoma (SCC) cells to apoptosis, along with the release of both HMGB1 and ATP and the exposure of CRT. This may be due to the enhancement of an immune response against SCCVII by RH2 in a SCC cancer model (47) .
Coxsackievirus B3-treated human non-small cell lung cancer (NSCLC) cells undergo ICD, comprising CRT surface exposure, release of HMGB1, and secretion of ATP in apoptotic tumor cells (47) . Ad5/3-hTERT-E1A-hCD40L, a novel oncolytic adenovirus having the chimeric Ad5/3 capsid, increases its antitumor efficacy. Ad5/3-hTERT-E1A-hCD40L increased the exposure of CRT and released HMGB1 and ATP, which were suggestive of immunogenicity (20) .
RIG-I-like helicases (RLH) can trigger an antiviral response in susceptible cells via the generation of IFN-I and apoptosis. Murine pancreatic cancer cell lines treated with RLH ligands generated IFN-I and the proinflammatory cytokines CXCL10 or IL-6. Furthermore, cancer cells died through intrinsic apoptosis with features of ICD, such as translocation of CRT to the outer cell membrane and release of HMGB1 and HSP70. IFN-I released from RLH-activated cancer cells induced the activation of DCs. Moreover, the immunogenic features of cancer cell death could be triggered by RLH activation in vivo (51) .
To enhance the contribution of immunogenic cell death, the combination of OV therapy with chemotherapy and/or immune-based therapeutic modalities was developed; OVs were often designed to express immune costimulatory genes. A study indicated that bortezomib combined with OV infection not only induced the complementary pathways of ER stress but also negatively interfered with recovery functions of the unfolded protein response in hepatocellular carcinoma, leading to an increased apoptotic phenotype of virus-induced cell death (52) .
Radiotherapy
The central dogma of traditional radiotherapy is its antitumor effect by inducing DNA double-strand breaks followed by cell death via apoptosis, necrosis, autophagy, mitotic catastrophe or replicative senescence (53) . Radiotherapy, in addition to the direct cytocidal effect on cancer cells, also has immune modulatory ability. A study indicated that radiation can reduce distant tumor growth mediated by the immune cells (54) . A few mechanisms have been proposed to explain the occurrence of such an antitumor response after radiotherapy. Irradiation can induce a local inflammatory response that facilitates the recruitment of immune cells, in particular DCs, thus promoting antigen presentation.
The major mechanism of radiotherapy is the generation of ROS, alerting the immune system with "danger signals" or DAMPs (3). A study indicated that radiotherapy induces ICD of tumor cells and regulates antigen presentation by altering the tumor microenvironment (55) . After being irradiated with an alpha particle emitter, cancer cells have a long-term antitumor immune response mediated by specific T cells in vivo. Irradiation of MC-38 cells with 213 Bi led to the release of DAMPs and the activation of DCs (56) . When breast, lung and prostate carcinoma cells were irradiated at sublethal doses, the secretion of ATP and HMGB1 as well as the cell-surface expression of CRT increased the susceptibility of tumor cells to CD8+ CTL-mediated lysis (57) . Ionizing radiation also induces dying colorectal tumor cells to release considerable amounts of karyopherin-α2 (KPNA2). KPNA2 acts as a DAMP in triggering antitumor immune responses. KPNA2 also activates DCs, induces them to mature, and subsequently increases T-cell proliferation. The antitumor immune response is activated (58).
The inducers of ICD 4 Under most circumstances, radiotherapy alone is a poor inducer of immune-mediated local and abscopal effects. Combinations of radiotherapy and chemotherapeutic agents are more effective. Combination of irradiation and bortezomib can more effectively induce the specific immune response against cancer cells than irradiation alone. The combined treatment further enhanced the apoptosis of cancer cells through the FAS and TRAIL signaling pathway, and significantly increased the ability of tumor-specific CD8+ T cells to kill tumor cells (59) . Radiation also induces ICD of TSA mammary cancer cells in a dose-dependent manner and improves platinum-chemotherapy-induced ICD when given simultaneously (60) .
Photodynamic therapy
Photodynamic therapy (PDT) was discovered more than 100 years ago as a successful and minimally invasive therapeutic modality to treat diverse solid tumors and some nonmalignant diseases. The main mechanisms of the antitumor effect of PDT are a direct cytotoxic effect on tumor cells, indirect damage to the tumor vasculature, and the activation of an antitumor immune response. The action of PDT relies on 3 major components: photosensitizer, visible light and oxygen molecular. PDT involves 2 steps: first, the photosensitizing agent, preferentially restricted to the subcellular region of the tumor cells, is activated by light of an appropriate wavelength; second, the light energy leads to the production of ROS in the presence of oxygen (61, 62) . The ROS cause oxidative damage to proteins, lipids and other intracellular molecules, leading to cancer cell apoptosis, necrosis or autophagy. This effect also injures the microvasculature and leads to a local inflammatory reaction (61, 63) .
Recent studies demonstrated that PDT can induce ER stress, immunogenic apoptosis of cancer cells, and generation of several DAMPs. The best known DAMPs induced by PDT are the HSP family (HSP70 and HSP90), CRT, HMGB1 and ATP. DAMPs released from PDT-treated tumor cells are the key players in the immunogenicity of tumor cells, shaping a unique environment with tumor antigens and danger signals to activate DC maturation (61, 64, 65) .
There are a few ICD-inductive photosensitizers: photofrin, hypericin, G-chlorin and 5-aminolevulinic acid (ALA). Very recently, rose bengal, a powerful photosensitizer, was found to be able to induce apoptosis of tumor cells with the properties of ICD such as the exposure and release of DAMPs (61, 62, (64) (65) (66) .
ALA is a photosensitizer in PDT (67) . ALA-PDT is capable of inducing tumor cell death via both apoptotic and necrotic pathways at different light doses. Under 0.5 J/cm 2 fluence, the proportion of apoptotic PECA cells reached its maximum, while 2 J/cm 2 fluence induced PECA cells to mainly undergo necrosis (64) . ALA-PDT-triggered apoptosis of cancer cells is more competent in potentiating DC maturation than PDTtreated or freeze/thaw-treated tumor cells. The ALA-PDT-DC vaccine can activate the adaptive immune system more effectively than the DC vaccine obtained from freeze/thaw-treated cancer cells (64) .
Glycoconjugated chlorin (G-chlorin) has been developed as a new photosensitizer. It was found that PDT with G-chlorin suppressed CT26 tumor growth much more efficiently in immunocompetent mice than in immunodeficient mice. This treatment also induced CRT translocation and HMGB1 release in tumor cells. PDT-treated cells can also be used as a tumor vaccine. Mice inoculated with PDT-treated tumor cells were observably protected against a subsequent challenge with the same live tumor cells (67) .
In terms of its immunogenicity, hypericin is regarded as one of the most powerful photosensitizers. Several studies indicated that hypericin-based PDT led to immunogenic tumor cell death (3). The capability of PDT to trigger a systemic antitumor immune response derives from the elicited acute inflammatory reaction and induced immunogenic tumor cell death. Evidence demonstrated that PDT-killed tumor cells trigger a stronger antitumor immune response in vivo than cancer cell lysates generated by UV and ionizing irradiation or freeze-thawing (62).
High hydrostatic pressure
High hydrostatic pressure (HHP), a physical modality, was found to induce ICD in both murine and human tumor cells (21, 68, 69) . HHP triggers the release of HMGB1 and ATP as well as fast expression of HSP70, HSP90 and CRT on the cancer cell surface. The interaction between DCs and HHP-treated cancer cells elicits the expression of maturation-associated molecules (CD83, CD86 and HLA-DR) on DCs and the production of proinflammatory cytokines (IL-6, IL-12p70 and TNF-α) in a wide range of primary human tumor cells and cancer cell lines. DCs pulsed with HHP-treated tumor cells induced high numbers of tumor-specific T cells (21) . This indicated that HHP as well as other modalities such as PDT, OVs, irradiation, and treatment with specific cytotoxic agents is able to trigger an effective antitumor immune response (70) . HHP is also applied to inactivate cancer cells before they are used as cellular vaccines or as antigen donors in DC-based vaccines.
HHP at 200 MPa induced immunogenic cell death when applied to both TRAMP-C2 and TC-1 cancer cells. HHP also induced cancer cells to express more CRT, HSP90 and HMGB1, and prompted DCs to mature (71) .
Combinatorial regimens
In the tumor immunotherapy strategy, tumor cells are often eliminated by combination therapy rather than by a single treatment. The combination of oncolytic adenoviruses and certain low-dose chemotherapeutics triggered ICD in tumor cells (72) . The combination of radiotherapy and mild hyperthermia induced higher levels of HSP70 and HMGB1 in B16 melanoma cells than either therapy alone. More immune cells infiltrated into the tumor tissue (73) .
To increase the effect of chemotherapy, a popular way to shift non-ICD to ICD is to combine chemotherapy drugs without ICD-inducing properties with an ICD-inducing substance. In contrast to other cytotoxic agents (such as oxaliplatin), cisplatin fails to induce ICD because of its weak inducibility of ER stress. ER stress is a prerequisite for the exposure of CRT to the tumor cell surface (74) . To attain ICD, ER stress can be induced via diverse approaches. Studies indicated that thapsigargin and tunicamycin had the potential to induce ER stress and therefore to restore the immunogenicity of cisplatintreated cancer cell death (74, 75) . The study by Menger et al (76) indicated that both digoxin and digitoxin were powerful ICD inducers and restored the immunogenicity of cisplatin and mitomycin C. The interaction of cisplatin with pyridoxine had a synergistic therapeutic effect in an orthotopic mouse model of NSCLC. The synergy was observed in immunocompetent mice but absent in immunodeficient mice. In vitro, the combination of cisplatin and pyridoxine led to more CRT exposure and more ATP and HMGB1 release than either cisplatin or pyridoxine alone. These results support that cisplatin combined with pyridoxine can induce ICD (77) .
The combination of 2-deoxyglucose and etoposide prolonged the life span of immunocompetent mice but not immunodeficient mice, and the combination activated tumor-specific T cells in vitro. This effect was at least partially mediated through ERp57/CRT exposure on the plasma membrane (78) .
The combination of the epigenetic modulator apicidin and docetaxel induced immunogenic apoptosis of metastatic breast cancer cells. The release of considerable amounts of HMGB1 and the exposure of CRT on the cell surface potentially favored an antitumor immune response (79) .
Increasing evidence is emerging that a typical trait of pancreatic ductal adenocarcinoma is hypoxia associated with an immune-suppressive milieu. Combined immunochemotherapy based on ICD induced by gemcitabine and a hypoxia-inducible factor-1 inhibitor, PX-478, exerted a synergistic effect on pancreatic cancer. Pancreatic cancer cells treated with gemcitabine and PX-478 provoked ER stress leading to the release of DAMPs such as HMGB1 and ATP. DAMP exposure triggered DC maturation/phagocytosis and IFN-γ secretion by CTLs. The combined administration of gemcitabine and PX-478 might elicit a synergistic immunological response to tumor (80) .
All these studies suggest that some agents have the ability to convert non-immunogenic cell death into bona fide ICD. Therefore, these agents may be employed as immunological adjuvants.
Other agents
Shikonin, a phytochemical derived from the medicinal plant Lithospermum erythrorhizon, served as an efficacious adjuvant to induce ICD in treated carcinoma cells (3, 22) . Moreover, the shikonin-treated tumor cell lysate facilitated the full maturation of DCs and accelerated the differentiation of Th1 and Th17 cells. In addition, shikonin-treated tumor cell lysate-loaded DC vaccines resulted in a strong immune response against the targeted tumor cells and in retardation of tumor growth (22) . The heterogeneous nuclear ribonucleoprotein A1 was a specific molecular target of shikonin (4), and played a vital role in lymphocyte-induced ICD in targeted cells (4, 81) .
Capsaicin is the principal component of hot peppers. A study indicated that it had the ability to bring about pain relief, weight loss and tumor prevention (82) . Capsaicin induced immunogenic apoptosis in PEL cells via translocation of HSP90 and CRT to the cell surface. It also impaired PEL cell survival by lessening STAT3 phosphorylation (83) . PEL cells re- leased multiple cytokines and soluble factors, which impaired monocyte differentiation into functional DCs (84) . Mediated by factors released from PEL cells, capsaicin was shown to counteract the effects on immune suppression and rescue monocyte differentiation into DCs (85) . In human bladder cancer cell lines, capsaicin induced ICD by surface exposure of CRT, HSP90, HSP70 and ATP (23) .
Conclusions
The immunogenicity or non-immunogenicity of tumor cell death depends on the initial stimulus. The concept of ICD was first proposed in the context of anticancer chemotherapy. The therapeutic effect of some traditional cytotoxic drugs depends on the specific immune responses of the host (84) . The ability of tumor treatment to trigger ICD relies on eliciting ROS and ER stress, both of which are prerequisites for inducing the intracellular danger signaling pathways that govern ICD (7, 26) .
ICD-inducing modalities such as PDT, HHP, OVT, chemotherapy and radiotherapy have been shown to trigger immune responses, acting as vaccines. In addition, shikonin and capsaicin also induce ICD. Exploiting these ICD inducers and other immunogenic modalities to obtain a highly immunogenic tumor cell is a promising strategy to elicit immune responses against tumor cells (Fig. 1) . Such responses are necessary for the full-blown efficacy of most (if not all) anticancer therapeutic regimens.
